Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/574
G01N-033/53
출원번호
UP-0366307
(2003-02-12)
등록번호
US-7704700
(2010-05-20)
발명자
/ 주소
Reed, John C.
Krajewski, Stan
출원인 / 주소
Burnham Institute for Medical Research
대리인 / 주소
McDermott Will & Emery LLP
인용정보
피인용 횟수 :
0인용 특허 :
5
초록▼
The invention provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a
The invention provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient.
대표청구항▼
What is claimed is: 1. A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising: (a) measuring the level of XIAP, wherein XIAP comprises SEQ ID NO:2, in a neoplastic prostate tissue sample from said patient, and (b) comparing the level of XIAP
What is claimed is: 1. A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising: (a) measuring the level of XIAP, wherein XIAP comprises SEQ ID NO:2, in a neoplastic prostate tissue sample from said patient, and (b) comparing the level of XIAP in said sample to a reference level of XIAP in non-transformed prostate cells, wherein an increased level of XIAP in said sample compared to the reference level indicates a prognosis of increased survival of said patient. 2. The method of claim 1, wherein said survival is overall survival. 3. The method of claim 1, wherein said survival is longer disease-free survival. 4. The method of claim 1, wherein said measuring comprises using an antibody specifically reactive with the sequence encoded by SEQ ID NO:2 of said XIAP. 5. The method of claim 1, wherein said patient has an early stage of prostate cancer. 6. The method of claim 1, wherein said level of XIAP is used to determine the proper course of treatment for said patient. 7. The method of claim 1, further comprising measuring the level of a second biomarker in said neoplastic prostate tissue sample and comparing the level of said second biomarker in said sample to a reference level of said second biomarker in non-transformed prostate cells, wherein the relative level of said second biomarker to said reference level indicates a prognosis for survival of said patient, wherein said second biomarker is an IAP biomarker selected from the group consisting of a cIAP2 polypeptide comprising SEQ ID NO:6, a cIAP1 polypeptide comprising SEQ ID NO:4, and Survivin. 8. The method of claim 7, wherein said IAP biomarker is the cIAP1 polypeptide comprising SEQ ID NO:4. 9. The method of claim 7, wherein said IAP biomarker is the cIAP2 polypeptide comprising SEQ ID NO:6. 10. The method of claim 7, wherein said IAP biomarker is Survivin. 11. The method of claim 1, further comprising measuring the level of a second biomarker in said neoplastic prostate tissue sample and comparing the level of said second biomarker in said sample to a reference level of said second biomarker in non-transformed prostate cells, wherein the relative level of said second biomarker to said reference level indicates a prognosis for survival of said patient, wherein said second biomarker is an IAP biomarker selected from the group consisting of a cIAP2 polypeptide comprising SEQ ID NO:6 and a cIAP1 polypeptide comprising SEQ ID NO:4. 12. The method of claim 11, wherein said IAP biomarker is the cIAP2 polypeptide comprising SEQ ID NO:6. 13. The method of claim 11, wherein said IAP biomarker is the cIAP1 polypeptide comprising SEQ ID NO:4. 14. A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising: (a) measuring a level of XIAP, wherein XIAP comprises SEQ ID NO:2, in a neoplastic prostate tissue sample from said patient, and (b) classifying said patient as belonging to either a first or second group of patients, wherein said first group of patients having a high level of XIAP relative to a reference level in non-transformed prostate cells is classified as having a prognosis for increased survival compared to said second group of patients having a low level of XIAP relative to said reference level. 15. The method of claim 14, wherein said survival is overall survival. 16. The method of claim 14, wherein said survival is longer disease-free survival. 17. The method of claim 14, wherein said measuring comprises using an antibody specifically reactive with the sequence encoded by SEQ ID NO:2 of said XIAP. 18. The method of claim 14, wherein said patient has an early stage of prostate cancer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (5)
Korneluk Robert G.,CAX ; MacKenzie Alexander E.,CAX ; Liston Peter,CAX ; Baird Stephen,CAX ; Tsang Benjamin K.,CAX ; Pratt Christine,CAX, Detection and modulation of IAPS for the diagnosis and treatment of proliferative disease.
El Shami A. Said (Agoura Hills CA) Alaba Olusola O. (Pasadena CA) Kasal Charles A. (South Pasadena CA), Method for measuring antigens or antibodies in biological fluids using ligand labeled antigens or ligand labeled antibod.
Korneluk Robert G.,CAX ; MacKenzie Alexander E.,CAX ; Liston Peter,CAX ; Baird Stephen,CAX ; Tsang Benjamin K.,CAX ; Pratt Christine,CAX, Modulation of IAPs for the treatment of proliferative diseases.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.